About us

Alligator Bioscience AB is a privately owned drug discovery and development company focused on optimization of biopharmaceuticals using its proprietary protein optimization technology FIND^® (Fragment INduced Diversity). 

FIND^® technology can redesign virtually any characteristics of a protein that can be translated into significant clinical benefits, including higher efficacy and potency, improved safety profile and decreased immunogenicity. The technology offers unique opportunities to discover novel protein drug candidates as well as creating second generation biopharmaceuticals. 

Projects are run independently or in partnership with other companies. Alligator Bioscience’s own pipeline of novel and improved drug candidates is focused on inflammation and cancer. Currently we are seeking industrial partners for our programs targeting the C5a receptor (C5aR) and Interleukin 1 (IL-1). 

Founded in 2001 in Lund, Sweden, Alligator Bioscience has successfully collaborated with many companies in the pharmaceutical and biotech industry, improving customers’ proteins and helping them to build more competitive pipelines. Collaboration partners include Astra Zeneca, Bayer HealthCare and Wyeth.